RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+4.99%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
+$273M
Cap. Flow
+$275M
Cap. Flow %
11.97%
Top 10 Hldgs %
43.45%
Holding
85
New
20
Increased
27
Reduced
19
Closed
15
Avg Time Held
1 year
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$73.7M
2
ABT icon
Abbott
ABT
+$49.7M
3
BLUE icon
bluebird bio
BLUE
+$40.7M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$37.3M
5
TFX icon
Teleflex
TFX
+$35.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.2M
2
AET
Aetna Inc
AET
+$37.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$34.4M
4
MOH icon
Molina Healthcare
MOH
+$31.7M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.29%
2 Financials 1.18%
3 Miscellaneous 0.94%
4 Communication Services 0.58%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$32.4M 1.41%
2,318,387
+266,900
+13% +$3.91M
2013 Q4
16 quarters
ELGX
27
DELISTED
Endologix Inc
ELGX
$31.7M 1.38%
592,810
-61,658
-9% -$3.26M
2015 Q4
8 quarters
ICUI icon
28
ICU Medical
ICUI
$4.07B
$30.2M 1.31%
139,972
-61,778
-31% -$12.5M
2017 Q1
3 quarters
XNCR icon
29
Xencor
XNCR
$1.79B
$29.6M 1.29%
1,350,894
+150,600
+13% +$3.27M
2016 Q4
4 quarters
BOLD icon
30
DELISTED
Audentes Therapeutics, Inc
BOLD
$29M 1.26%
929,326
-360,006
-28% -$9.88M
2016 Q3
5 quarters
WCG
31
DELISTED
Wellcare Health Plans, Inc.
WCG
$29M 1.26%
+144,349
New +$27.9M
2017 Q4
0 quarters
EHTH icon
32
eHealth
EHTH
$19.2M
$27.1M 1.18%
1,558,914
+221,291
+17% +$4.95M
2016 Q4
4 quarters
MDRX
33
DELISTED
Veradigm Inc. Common Stock
MDRX
$25.8M 1.12%
+1,770,600
New +$24.6M
2017 Q4
0 quarters
UHS icon
34
Universal Health Services
UHS
$10.9B
$24.6M 1.07%
+217,100
New +$23.2M
2017 Q4
0 quarters
EPZM
35
DELISTED
Epizyme, Inc
EPZM
$24.2M 1.05%
1,925,689
+715,689
+59% +$10.4M
2017 Q3
1 quarter
ANAB icon
36
AnaptysBio
ANAB
$1.39B
$23.1M 1.01%
+229,850
New +$16.9M
2017 Q4
0 quarters
PRAH
37
DELISTED
PRA Health Sciences, Inc.
PRAH
$22.8M 0.99%
250,614
-151,400
-38% -$12.6M
2017 Q3
1 quarter
NITE icon
38
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$21.9M 0.95%
1,772,846
+3,500
+0.2% +$62.9K
2017 Q3
1 quarter
NVTA
39
DELISTED
Invitae Corporation
NVTA
$20.2M 0.88%
2,222,040
+109,800
+5% +$984K
2015 Q1
11 quarters
CBAY icon
40
DELISTED
Cymabay Therapeutics
CBAY
$18.4M 0.8%
2,002,265
+355,165
+22% +$3.04M
2017 Q3
1 quarter
IFRX icon
41
InflaRx
IFRX
$220M
$18M 0.78%
+857,300
New +$15.5M
2017 Q4
0 quarters
CMRX icon
42
DELISTED
Chimerix, Inc.
CMRX
$17.7M 0.77%
3,832,778
-392,797
-9% -$1.87M
2016 Q2
6 quarters
LUMO icon
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$17M 0.74%
232,943
+94,199
+68% +$7.79M
2017 Q3
1 quarter
HSKA
44
DELISTED
Heska Corp
HSKA
$15.8M 0.68%
+196,396
New +$17.3M
2017 Q4
0 quarters
ODT
45
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$14.9M 0.65%
+596,900
New +$14.1M
2017 Q4
0 quarters
DCPH icon
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.7M 0.64%
683,880
-39,000
-5% -$764K
2017 Q3
1 quarter
MODN icon
47
DELISTED
MODEL N, INC.
MODN
$13.4M 0.58%
853,714
+14,800
+2% +$223K
2013 Q4
16 quarters
ARGX icon
48
argenx
ARGX
$52B
$12.6M 0.55%
+200,000
New +$6.55M
2017 Q4
0 quarters
JNCE
49
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$12.5M 0.54%
980,393
+24,795
+3% +$364K
2017 Q1
3 quarters
ASXC icon
50
DELISTED
Asensus Surgical, Inc.
ASXC
$9.68M 0.42%
+385,984
New +$11.9M
2017 Q4
0 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2017 Portfolio in Review

As of Q4 2017, Redmile Group held 85 positions worth $2.3B, up 13% from $2.03B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $275M of net new capital in Q4 2017, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was Celgene Corp: 653,000 shares worth $68.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $40.2M trimmed.

  • Redmile Group's largest Q4 2017 buy was Celgene Corp: 653,000 shares worth $68.1M.
  • Redmile Group added most to Syneos Health, Inc. Class A Common Stock in Q4 2017, an estimated $37.3M increase.
  • Redmile Group's biggest Q4 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $40.2M.
  • Redmile Group fully exited Aetna Inc in Q4 2017, selling an estimated $37.2M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q4 2017.
  • Redmile Group opened 20 new positions and closed 15 in Q4 2017.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.